Research

FAST is the largest non-governmental funderof Angelman syndrome research.

FAST Funded Research

FAST Funded
Research

Learn More
Learn More
Current Trials

Current Trials
& Studies in AS

Participate
Participate
Hear from Researchers

2020 Science
Summit

Watch
Watch
Roadmap

Roadmap
to a Cure

Download
Coming Soon
Grant App

Research Grant
Application

Apply
Apply

Roadmap to a Cure

FAST’s Roadmap is focused on three elements supporting therapeutic approaches that have the potential to reverse the effects of the disorder in children, teens and adults. 

Gene Therapy

FAST is funding research in gene or protein replacement therapy and gene activation therapy. Human clinical trials are underway today!
Gene or protein replacement therapy delivers healthy copies of the UBE3A gene or protein to compensate for the missing or underperforming gene. Treatment is delivered via AAV or Lentivirus (stem cell).

Gene activation therapy, in AS referred to as “stop the stop”, works to activate the normally silent paternal gene to compensate for the underperforming or missing maternally inherited gene. Treatment is delivered via ASO, ATO, or CRISPR. 

Downstream Therapy

Downstream therapy uses drugs to treat the symptoms of Angelman syndrome like seizures, sleep, and communication. There are many drugs that are already approved by the FDA that might be useful for treating AS. Finding these drugs and showing that they can be repurposed brings new treatments for AS.
Therapeutics being targeted often improve synaptic function and communication between neurons in the brain thus increasing tonic inhibition and improving quality of life. Different strategies being pursued include: novel compounds or peptides, Ketone supplements, anti-inflammatory or regenerative medicines, and GABA replacement.

Prepare!

FAST supports the Global AS Registry and Natural History studies that collect key data from those living with AS such as: communication, sleep, gross/fine motor, and seizures. This data is used to inform research and trials.
Angelman Biomarker Outcome Measures (ABOM) consortium was established to collaborate across AS patient centered organizations, pharmaceuticals, and researchers to determine what biomarkers and measures would be most impactful to individuals for assessment in clinical trials.
FAST funded animal models with various genotypes to ensure that therapeutics can be tested against the various AS genotypes.
Printable Version Coming Soon
Printable Version Coming Soon

FAST is the driving force behind research for a cure.

Angelman SyndromeAntisense Oligonucleotide Therapy

Antisense oligonucleotides (ASOs) used in the treatment of Angelman syndrome focus on preventing the paternal UBE3A gene from being silenced – a condition caused by the UBE3A antisense transcript (UBE3A-AS). By “knocking down” the UBE3A-AS, the paternal gene becomes active, expressing functional UBE3A. ASOs are delivered intermittently through a lumbar puncture into the CSF and, while not a one-time treatment, can be repeatedly administered to a patient over a long-term.
ASO
Play Video

FAST’s Infrastructure Program

David Segal, Ph.D., Jill Silverman, Ph.D., and the team at the University of California, Davis received a grant from FAST to build a lab devoted to Angelman syndrome (AS) research, establishing a stable infrastructure in which this team can evaluate multiple therapeutics simultaneously through, at least 2025. The Infrastructure Grant will create a new generation of scientists focused on AS research with combined expertise in molecular and behavioral components of AS; provide lab equipment and supplies; maintain AS cell lines and rodent model colonies at the University and provide long-term stability for this dedicated team to keep their focus on identifying and evaluating potential therapeutics for the treatment of Angelman syndrome.
Multiple pharmaceutical companies have potentially promising therapeutics for the treatment of AS. However, they do not have expertise in AS, or the specific tools necessary to properly evaluate these drugs for this population. This Infrastructure Grant allows AS experts to provide those services and elucidate if a potential therapeutic warrants further development toward potential human clinical trials.
UC Davis
Play Video
Segal David

David Segal Ph.D.

Position: Professor
 

UC Davis Genome Center, Department of Biochemistry and Molecular Medicine, Pharmacology,
MIND Institute,
UC Davis School of Medicine
Visit Website
Specialty: Genomic therapeutics

Segal David

David Segal Ph.D.

Professor
 
j silverman

Jill Silverman Ph.D.

Position: Assistant Adjunct Professor

Department of Psychiatry and Behavioral Sciences; University of California Davis School of Medicine
View Website
Speciality: preclinical translational evaluation of pharmacological treatments for autism spectrum disorders

j silverman

Jill Silverman Ph.D.

Assistant Adjunct Professor

The Impact

A cure for Angelman syndrome will have a tremendous impact on society at large. The gene that causes Angelman syndrome has been linked to several other diseases and genetic disorders involving learning and memory. The work FAST researchers are doing may be the gateway to therapies for other disorders that affect the lives of millions, especially those with other neurodevelopmental disorders.
Impact
Play Video

FAST Funded Research

Genetic Diagnosis Campaign in Argentina | $18,000
Description:

Casa Angelman developed a National Genetic Campaign to provide testing for children across Argentina and with assistance from FAST, will be able to bridge that gap for many Argentinian families.

Year:
2020
Principal Investigator:
Grant #:
GIA2020-001: 2020-2021
Read More
Generation and Characterization of a New Angelman syndrome Mouse Model that Recapitulates the Large Deletion of Human 15q11-q13 and a Control Line that Carries a Deletion of all Genes in 15q11-q13 but UBE3A | $886,894
Description:

Dr. Jiang will create a novel ~6MB full deletion Angelman syndrome mouse model. As we near a therapeutic aimed at getting a working copy of UBE3A into humans living with Angelman syndrome (AS), this work will contribute to the understanding of the other genes impacted in the largest population of individuals living with AS, those with a large deletion (>70% of individuals with AS), including numerous other genes around UBE3A and how these haploinsufficient genes may be contributing to symptoms of deletion positive individuals.

Year:
2020
Principal Investigator:
Y. Jiang
Grant #:
FT2020-006: 2020-2023
Read More
Translational Analysis of Gait as a Primary Outcome Measure in Angelman Syndrome | $282,870
Description:

Dr. Duis used the ActiMyo device(s) in a clinical study to evaluate the tolerability and gait parameters in Angelman syndrome. This device was shown to be well  tolerated and associated with various unique gait parameters when compared to neurotypical age-matched controls.

Year:
2020
Principal Investigator:
J. Duis and J. Silverman
Grant #:
FT2020-005: 2020-2021
Read More
Load More
pipeline3

Helpful Resources

can3.1.21
As diverse as our Angelman community is, we are all united in one goal: a better future for our children. FAST is committed to bringing life-changing treatments to all individuals with Angelman syndrome, but we need your help!
Start Fundraising
Start Fundraising
Start Fundraising
Start Fundraising
can3.1.21
As diverse as our Angelman community is, we are all united in one goal: a better future for our children. FAST is committed to bringing life-changing treatments to all individuals with Angelman syndrome, but we need your help!
Start Fundraising
Start Fundraising
Start Fundraising
Start Fundraising
X
X